ZA201803719B - Stable solid dispersions of eliglustat hemitartrate - Google Patents
Stable solid dispersions of eliglustat hemitartrateInfo
- Publication number
- ZA201803719B ZA201803719B ZA2018/03719A ZA201803719A ZA201803719B ZA 201803719 B ZA201803719 B ZA 201803719B ZA 2018/03719 A ZA2018/03719 A ZA 2018/03719A ZA 201803719 A ZA201803719 A ZA 201803719A ZA 201803719 B ZA201803719 B ZA 201803719B
- Authority
- ZA
- South Africa
- Prior art keywords
- solid dispersions
- stable solid
- eliglustat hemitartrate
- eliglustat
- hemitartrate
- Prior art date
Links
- KUBARPMUNHKBIQ-VTHUDJRQSA-N eliglustat tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 KUBARPMUNHKBIQ-VTHUDJRQSA-N 0.000 title 1
- 239000007962 solid dispersion Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201721019661 | 2017-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201803719B true ZA201803719B (en) | 2019-04-24 |
Family
ID=62791787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/03719A ZA201803719B (en) | 2017-06-05 | 2018-06-05 | Stable solid dispersions of eliglustat hemitartrate |
Country Status (2)
| Country | Link |
|---|---|
| WO (1) | WO2018225085A1 (en) |
| ZA (1) | ZA201803719B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2395463T3 (en) | 2001-07-16 | 2013-02-15 | Genzyme Corporation | An N-acylphingosine glucosyltransferase inhibitor |
| ME02477B (en) | 2009-11-27 | 2017-02-20 | Genzyme Corp | Genz 112638 for the treatment of Gaucher or Fabry disease in combination therapy |
| CA2954030A1 (en) | 2014-07-03 | 2016-01-07 | Dr. Reddy's Laboratories Limited | Amorphous form of eliglustat hemitartarate |
| ES2716420T3 (en) | 2015-04-14 | 2019-06-12 | Sandoz Ag | Crystalline eliglustat hydrochloride |
-
2018
- 2018-06-05 ZA ZA2018/03719A patent/ZA201803719B/en unknown
- 2018-06-05 WO PCT/IN2018/050362 patent/WO2018225085A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018225085A1 (en) | 2018-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275365A (en) | 6-azaindole compounds | |
| IL272888B1 (en) | Novel uses of piperidinyl-indole derivatives | |
| IL250511A0 (en) | Solid state forms of ibrutinib | |
| EP3438474B8 (en) | Piece of furniture | |
| HU4602U (en) | Set of saggar assembly | |
| IL269409A (en) | Combinations of chk1- and wee1 - inhibitors | |
| HUE056357T2 (en) | Derivatives of sobetirome | |
| SI3524234T1 (en) | Solid state forms of sofosbuvir | |
| IL274627A (en) | Solid state form of valbenazine | |
| IL265628A (en) | Solid state forms of valbenazine | |
| PT3661491T (en) | Use of 3-methylmethcathinone | |
| IL256159B (en) | Solid dispersions of coenzyme q10 | |
| IL246979A0 (en) | Solid state forms of sofosbuvir | |
| ZA201706282B (en) | Solid forms of menaquinols | |
| EP3384921A4 (en) | New use of thiopeptin | |
| EP3468578A4 (en) | Uses of il-41 | |
| IL263673A (en) | Solid state forms of spiro-oxindole compounds | |
| HU4603U (en) | Set of saggar assembly | |
| HUE050745T2 (en) | Use of levelling compound | |
| GB201602857D0 (en) | Connection of rotatable parts | |
| IL263363A (en) | Polymorph of nintedanib | |
| ZA201808437B (en) | Determination of feedback timing | |
| ZA201803719B (en) | Stable solid dispersions of eliglustat hemitartrate | |
| GB2553887B (en) | Arrangement of line connections | |
| IL254666A0 (en) | Solid state form of eldecalcitol |